Ocugen Aims for Three BLA Filings in Next Three Years Amid Gene Therapy Expansion

Ocugen plans to file three Biologics License Applications (BLAs) in the next three years, expanding its global gene therapy presence. The company's CEO, Shankar Musunuri, highlighted the rapid progress of its modifier gene therapy platform, bringing its lead candidate, OCU400, from initial Phase 1/2 dosing to nearing Phase 3 enrollment in just over three years.